New therapeutic strategies in chronic hepatitis C;Nouvelles stratégies thérapeutiques dans l'hépatite chronique C

Gastroenterologie Clinique et Biologique

Volumn 30, Issue 8-9, 2006, Pages 1009-1011

  Pawlotsky, Jean Michel ^a,b  

^a UNIVERSITÉ PARIS EST CRÉTEIL   (France)

^b HENRI MONDOR HOSPITAL   (France)

Author keywords

[No Author keywords available]

Indexed keywords

ALBUMIN ALPHA INTERFERON; ALPHA INTERFERON; ANTIVIRUS AGENT; CPG 10101; CYCLOSPORIN; DNA VACCINE; HCV 796; HEPATITIS C VACCINE; IMMUNOGLOBULIN ANTIBODY; ISATORIBINE; PEGINTERFERON ALPHA2B; POLYCLONAL ANTIBODY; PROTEINASE INHIBITOR; RECOMBINANT ANTIGEN; RIBAMIDINE; RIBAVIRIN; SCH 503034; TELAPREVIR; UNCLASSIFIED DRUG; VX 950;

CELLULAR IMMUNITY; CLINICAL TRIAL; DRUG EFFECT; DRUG EFFICACY; DRUG SAFETY; EDITORIAL; HEMOLYTIC ANEMIA; HEPATITIS C; HUMAN; NONHUMAN; TREATMENT OUTCOME; TREATMENT RESPONSE; VACCINATION; VIRUS INFECTION; VIRUS INHIBITION; VIRUS REPLICATION; VIRUS VIRULENCE;

EID: 33750724445     PISSN: 03998320     EISSN: None     Source Type: Journal    
DOI: 10.1016/s0399-8320(06)73375-9     Document Type: Editorial

References (17)

1. Pawlotsky JM. Therapy of hepatitis C: from empiricism to eradication. Hepatology 2006;43:S207-20.
2. Rustgi V, Nelson D, Balam V, Sulkowski M, Lambiase L, Davis G, et al. A phase 2 dose-escalation study of Albuferon combined with ribavirin in nonresponders to prior interferon-based therapy for chronic hepatitis C virus infection. J Hepatol 2006;44(Suppl 2):S50.
3. Zeuzem S, Benhamou Y, Shouval D, Bain V, Pianko S, Flisiak R, et al. Interim (week 12) phase 2b virological efficacy and safety results of Albumin interferon alpha-2b combined with ribavirin in genotype 1 chronic hepatitis C virus infection. J Hepatol 2006;44(Suppl 2):S270.
4. Brideau-Andersen A, Huang X, Chang Sun S, Chen T, Stark D, Sas I, et al. Directed evolution of novel gene shuffled interferon alphas for the treatment of hepatitis C. J Hepatol 2006;44(Suppl 2):S6.
5. Horsmans Y, Berg T, Desager JP, Mueller T, Schott E, Fletcher SP, et al. Isatoribine, an agonist of TLR7, reduces plasma virus concentration in chronic hepatitis C infection. Hepatology 2005;42:724-31.
6. McHutchison JG, Bacon BR, Gordon SC, Lawitz E, Shiffman M, Afdhal NH, et al. Final results of a multicenter phase 1B, randomized, placebo-controlled, dose-escalation trial of CPG 10101 in patients with chronic hepatitis C virus. J Hepatol 2006;44(Suppl 2):S49.
7. McHutchison JG, Ghalib R, Lawitz E, Kwo P, Freilich B, Muir A, et al. Early viral response to CPG 10101 in combination with pegylated interferon and/or ribavirin in chronic HCV genotype 1 infected patients with prior relapse response. J Hepatol 2006;44(Suppl 2):S269.
8. Benhamou Y, Pockros P, Rodriguez-Torres M, Gordon S, Shiffman M, Lurie Y, et al. The safety and efficacy of viramidine plus pegylated interferon alpha-2b versus ribavirin plus pegylated interferon alpha-2b in therapy-naïve patients infected with HCV: phase 3 results. J Hepatol 2006;44(Suppl 2):S273.
9. Paeshuyse J, Kaul A, De Clercq E, Rosenwirth B, Dumont JM, Scalfaro P, et al. The non-immunosuppressive cyclosporin DEBIO-025 is a potent inhibitor of hepatitis C virus replication in vitro. Hepatology 2006;43:761-70.
10. Leroux-Roels G, Depla E, Hulstaert F, Tobback L, Dincq S, Desmet J, et al. A candidate vaccine based on the hepatitis C E1 protein: tolerability and immunogenicity in healthy volunteers. Vaccine 2004;22:3080-6.
11. Soler M, McHutchison JG, Kwoh TJ, Dorr FA, Pawlotsky JM. Virological effects of ISIS 14803, an antisense oligonucleotide inhibitor of hepatitis C virus (HCV) internal ribosome entry site (IRES), on HCV IRES in chronic hepatitis C patients and examination into the potential role of primary and secondary HCV resistance in the outcome of treatment. Antiviral Ther 2004;9:953-68.
12. Reesink HW, Zeuzem S, Weegink CJ, Forestier N, van Vliet A, van de Wetering de Rooij J, et al. Final results of a phase 1b, multiple-dose study of VX-950, a hepatitis C virus protease inhibitor. Hepatology 2005;42(Suppl 1):234A.
13. Zeuzem S, Sarrazin C, Wagner F, Rouzier R, Forestier N, Gupta S, et al. The HCV NS3 protease inhibitor SCH 503034 in combination with Peg-IFN alpha-2b in the treatment of HCV-1 Peg-IFN alpha-2b nonresponders: antiviral activity and HCV variant analysis. J Hepatol 2006;44(Suppl 2):S35.
14. Kieffer T, Sarrazin C, Bartels D, Hanzelka B, Müh U, Welker M, et al. Wild-type HCV NS3 protease re-emerges during follow-up after 14 days of dosing with VX-950 in patients with genotype 1 HCV. J Hepatol 2006;44(Suppl 2):S7.
15. Afdhal N, O'Brien C, Godofsky E, Rodriguez-Torres M, Pappas SC, Pockros P, et al. Valopicitabine (NM283), alone or with peginterferon, compared to peginterferon-ribavirin (PEGIFN/RBV) retreatment in hepatitis C patients with prior nonresponse to PEGIFN/RBV: week 24 results. J Hepatol 2006;44(Suppl 2):S19.
16. Dieterich D, Lawitz E, Nguyen T, Younes Z, Santoro J, Gitlin N, et al. Early clearance of HCV RNA with valopicitabine (NM283) plus peginterferon in treatment-naive patients with HCV-1 infection: first results from a phase IIb trial. J Hepatol 2006;44(Suppl 2):S271.
17. Roberts S, Cooksley G, Shaw D, Berns HK, Brandl MT, Fettner SH, et al. Interim results of a multiple ascending dose study of R1626, a novel nucleoside analog targeting HCV polymerase in chronic HCV patients. J Hepatol 2006;44(Suppl 2):S269.